Rainer Oberbauer
Overview
Explore the profile of Rainer Oberbauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
275
Citations
4523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gao T, Kastriti M, Ljungstrom V, Heinzel A, Tischler A, Oberbauer R, et al.
Nat Genet
. 2023 Oct;
55(11):1901-1911.
PMID: 37904053
Genetic mutations accumulate in an organism's body throughout its lifetime. While somatic single-nucleotide variants have been well characterized in the human body, the patterns and consequences of large chromosomal alterations...
12.
Rathkolb V, Traugott M, Heinzel A, Poglitsch M, Aberle J, Eskandary F, et al.
iScience
. 2023 Oct;
26(11):108146.
PMID: 37867935
Despite the similar clinical outcomes after renin-angiotensin system (RAS) inhibitor (RASi) continuation or withdrawal in COVID-19, the effects on angiotensin-converting enzyme 2 (ACE2) and RAS metabolites remain unclear. In a...
13.
Mucha J, Cho A, Weijler A, Muckenhuber M, Hofmann A, Wahrmann M, et al.
Front Immunol
. 2023 Sep;
14:1179036.
PMID: 37731514
Introduction: Antibody mediated rejection (ABMR) is a major factor limiting outcome after organ transplantation. Anti-HLA donor-specific antibodies (DSA) of the IgG isotype are mainly responsible for ABMR. Recently DSA of...
14.
Aschauer C, Heinzel A, Stiasny K, Borsodi C, Hu K, Koholka J, et al.
Viruses
. 2023 Aug;
15(8).
PMID: 37631967
Sotrovimab, a monoclonal antibody against SARS-CoV-2, is used as a pre-exposition prophylaxis (PrEP) against COVID-19, but monitoring strategies using routine test systems have not been defined. Twenty kidney transplant recipients...
15.
Geroldinger A, Strohmaier S, Kammer M, Schilhart-Wallisch C, Heinze G, Oberbauer R, et al.
Nephrol Dial Transplant
. 2023 Jul;
39(1):36-44.
PMID: 37403325
Background: Kidney transplantation is the preferred treatment for eligible patients with kidney failure who need renal replacement therapy. However, it remains unclear whether the anticipated survival benefit from kidney transplantation...
16.
de Fijter J, Dreyer G, Mallat M, Budde K, Pratschke J, Klempnauer J, et al.
Kidney Int
. 2023 Jun;
104(3):552-561.
PMID: 37343659
The Eurotransplant Senior Program (ESP) has expedited the chance for elderly patients with kidney failure to receive a timely transplant. This current study evaluated survival parameters of kidneys donated after...
17.
Sourij H, Edlinger R, Prischl F, Kaser S, Horn S, Antlanger M, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):182-194.
PMID: 37101040
Epidemiological investigations have shown that approximately 2-3% of all Austrians have diabetes mellitus with renal involvement, leaving 250,000 people in Austria affected. The risk of occurrence and progression of this...
18.
Gregorich M, Kammer M, Heinzel A, Boger C, Eckardt K, Heerspink H, et al.
JAMA Netw Open
. 2023 Apr;
6(4):e231870.
PMID: 37017968
Importance: Type 2 diabetes increases the risk of progressive diabetic kidney disease, but reliable prediction tools that can be used in clinical practice and aid in patients' understanding of disease...
19.
Kammer M, Heinzel A, Hu K, Meiselbach H, Gregorich M, Busch M, et al.
Cardiovasc Diabetol
. 2023 Mar;
22(1):74.
PMID: 36991445
Background: Chronic kidney disease (CKD) is a common comorbidity in people with diabetes mellitus, and a key risk factor for further life-threatening conditions such as cardiovascular disease. The early prediction...
20.
Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, et al.
Transplantation
. 2023 Mar;
107(7):1593-1604.
PMID: 36959121
Background: The comparative impact of everolimus (EVR)-based regimens versus standard of care (mycophenolic acid+standard calcineurin inhibitor [MPA+sCNI]) on cardiovascular outcomes in de novo kidney transplant recipients (KTRs) is poorly understood....